In a significant move to diversify its oncology offerings, Bristol Myers Squibb is acquiring Mirati Therapeutics for over $4.8 billion, with the potential for additional milestone payments of $1 billion. This acquisition includes Mirati's FDA-approved non-small cell lung cancer drug, Krazati